Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and Safety of SAR156597 in the Treatment of Diffuse Cutaneous Systemic Sclerosis (dcSSc): A Randomized, Double-blind, Placebo-controlled, 24-week, Proof of Concept Study

Next Previous
X
Search
Trial Profile

Efficacy and Safety of SAR156597 in the Treatment of Diffuse Cutaneous Systemic Sclerosis (dcSSc): A Randomized, Double-blind, Placebo-controlled, 24-week, Proof of Concept Study

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 04 Feb 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Romilkimab (Primary)
  • Indications Diffuse scleroderma
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Sanofi

    • Most Recent Events

    • 22 Sep 2020 Results assessing efficacy and safety of romilkimab in patients with early Diffuse Cutaneous Systemic Sclerosis (dcSSc), published in the Annals of the Rheumatic Diseases.
    • 06 Jun 2020 Results presented at the 21st Annual Congress of the European League Against Rheumatism
    • 08 Apr 2019 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top